APTO News and Press, Aptose Biosciences Inc. From 11/24/20

Nonsteroidal anti-inflammatory drugs, or NSAIDs are among the most widely used medications in the world for pain and inflammation. In fact, more than 33 million Americans use them regularly, and more than 30 billion doses of NSAIDs are administered annually in the U.S., according to Medicin...

Over the past 10-plus years, biotech stocks have been one of the best areas of the market to unearth hidden gems. Scores of pre-revenue drugmakers have delivered life-changing gains for their early shareholders over this period. Not every small- to mid-cap biotech stock is a proverbial diam...

Aptose shares have been weak of late, but there have been no negative updates to the company's core clinical programs, and management recently started its third trial (CG-806 in AML). It is unclear whether the upcoming ASH meeting will provide meaningful efficacy information on CG-806...

Aptose Biosciences Inc. (APTO) Q3 2020 Earnings Conference Call November 10, 2020 5:00 PM ET Company Participants Susan Pietropaolo – Communications Representative William Rice – Chairman, President and Chief Executive Officer Gregory Chow – Executive Vice President and C...

Aptose Biosciences (APTO): Q3 GAAP EPS of -$0.15 beats by $0.04.Total cash and equivalents and investments of $132.7M.Press Release For further details see: Aptose Biosciences EPS beats by $0.04

Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in APTO-253 Phase 1b Study in AML / MDS at Fifth (150mg/m 2 ) Dose Level ...

SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that early clinical data,...

SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended Septemb...

Gainers: Cassava Sciences (SAVA) +13%, Medigus (MDGS) +10%, STRATA Skin Sciences (SSKN) +9%, CASI Pharmaceuticals (CASI) +8%, BOQI International Medical (BIMI) +7%.Losers: Neovasc (NVCN) -14%, ProPhase Labs (PRPH) -14%, Mileston...

Aptose Biosciences ([[APTO]] +2.8%) announces dosing of the first patient with acute myeloid leukemia in a Phase 1 a/b clinical study with CG-806, the company’s oral kinase inhibitor.The investigational drug is the only known clinical agent that potently inhibits both FLT3 and BTK, giv...